$104.01
-0.70-0.67%
Last update: Nov 11, 7:00 AM
Edwards Lifesciences Corp
EWNYSE
Edwards Lifesciences rose 23.0% from $85.16 to a 1-year high of $104.71, ahead of the S&P 500's +9.8%. Its worst day was Feb 12 (−3.6%), and its low came Feb 13 at $75.87.
Nov 11, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $0.58 missed the $0.62 estimate on $1.6B revenue (est. $1.5B); FY revenue guidance of $6.6B–$6.7B against the $6.6B consensus.
+3.0% · S&P 500 0.0%
Story events cover the past 12 months · Times ET
EPS of $0.78 beat the $0.73 estimate on $1.6B revenue (est. $1.6B); FY revenue guidance of $6.5B–$6.9B against the $6.7B consensus.
+5.6%, the year's best day · S&P 500 +0.8%
EPS of $0.78 beat the $0.74 estimate on $1.7B revenue (est. $1.7B); Q3 revenue guidance of $1.6B–$1.7B against the $1.7B consensus.
−1.4% · S&P 500 +0.1%
Edwards Lifesciences shares rose 4.1%, while the S&P 500 fell 0.4%.
+4.1% · S&P 500 −0.4%
EPS of $0.80 beat the $0.74 estimate on $1.7B revenue (est. $1.7B); Q4 revenue guidance of $1.7B–$1.8B against the $1.7B consensus.
+1.5% · S&P 500 −4.4%
Where it ended: a 1-year high close of $104.71 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 9, 2027 (EPS est. $0.66, revenue est. $1.7B).
Nothing in the past 12 months.
All EW dividend historyReplay the year: the line draws itself and stops at each of the 5 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for EW and SPY from Benzinga historical bars. Not investment advice.
